JDRF IMPROVING LIVES. CURING TYPE 1 DIABETES.

Mark C. Poznansky, M.D., Ph.D.
Founder and Director, Vaccine and Immunotherapy Center (VIC), Massachusetts General Hospital (MGH)

Please join us as we celebrate exciting advances in type 1 diabetes (T1D) research. Dr. Mark Poznansky will speak about his extensive work testing a human protein that has the potential to enhance the long-term viability of encapsulated islet cells.

Cocktail and Hors d'oeuvres Reception

DATE

Thursday, November 14, 2019, 6:30 p.m.

LOCATION

The Bostonian Boston, 26 North Street, Boston, MA

RSVP

Space is limited. Kindly reply by Thursday, November 7, 2019 at https://jdrf-ne.org/SpeakerSeriesNov2019. You may also contact the JDRF office at 781-431-0700 or dgaboury@jdrf.org with any questions.

PARKING

Valet parking will be available at the hotel for $25.

Dr. Mark C. Poznansky is an associate professor at Harvard Medical School and a research scholar and attending physician in Transplant Infectious Diseases Medicine at Massachusetts General Hospital (MGH). He serves on the Commercialization Council at Partners Healthcare and is the scientific founder of several biotech companies, including Vicapsys. Dr. Poznansky founded the MGH Vaccine and Immunotherapy Center (VIC) ten years ago with the mission to accelerate the development of broadly applicable, safe, and cost-effective vaccines and immunotherapies for cancer, infectious diseases, and type 1 diabetes (T1D). The scientific teams at VIC work at the interface between scientific discovery and medical product development, and the focus of one program is on the transplantation of human stem cell derived Beta cells to provide dynamic insulin replacement in people with T1D, without immunosuppression.

As an active member of the JDRF Beta Cell Replacement Consortium, Dr. Poznansky, along with his team, has contributed significantly to the development of encapsulation therapy. With support from JDRF, this team continues to explore and optimize using CXCL12, which is naturally secreted by our immune system, to protect implanted beta cells against inflammation and immune attack in encapsulation systems without the use of immune suppressive drugs. Dr. Poznansky holds a doctoral degree from Cambridge University and a medical degree from the University of Edinburgh.